Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.49 |
| ▸ | SFRP1 | Q8N474 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29279184 | 0.83 | PIK3CD (0.49) | USP30SFRP1BRD4GPR119 | |
| SCHEMBL29874678 | 0.83 | STS (0.54) | USP30SFRP1BRD4GPR119STS | |
| SCHEMBL24242748 | 0.83 | STS (0.54) | USP30SFRP1BRD4GPR119STS | |
| SCHEMBL648715 | 0.81 | ALDH1A1 (0.57) | SFRP1GPR119STSCCR8 | |
| SCHEMBL6195397 | 0.80 | STS (0.58) | SFRP1BRD4GPR119STSCCR8 | |
| SCHEMBL20576339 | 0.79 | USP30 (0.68) | USP30SFRP1BRD4GPR119STS | |
| SCHEMBL13696749 | 0.79 | ALDH1A1 (0.53) | USP30SFRP1BRD4GPR119STS | |
| SCHEMBL30099305 | 0.79 | ALDH1A1 (0.53) | USP30SFRP1BRD4GPR119STS | |
| SCHEMBL10194537 | 0.78 | SFRP1 (0.53) | USP30SFRP1BRD4STSCCR8 | |
| SCHEMBL856401 | 0.78 | HSD17B10 (0.69) | USP30SFRP1BRD4CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| EP-3630096-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | Mission Therapeutics Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018220355-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | USP30, USP1, USP39 | USP30 1/4885SFRP1 4185/4885BRD4 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.